Detalhe da pesquisa
1.
An affinity tool for the isolation of endogenous active mTORC1 from various cellular sources.
J Biol Chem
; 299(5): 104644, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36965617
2.
The tumor suppressor FLCN mediates an alternate mTOR pathway to regulate browning of adipose tissue.
Genes Dev
; 30(22): 2551-2564, 2016 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27913603
3.
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
Br J Cancer
; 124(9): 1581-1591, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33723394
4.
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.
Proc Natl Acad Sci U S A
; 108(9): 3761-6, 2011 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21321214
5.
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Clin Cancer Res
; 26(14): 3720-3731, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32220884
6.
Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2.
Mol Cancer Res
; 6(9): 1491-8, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18819936
7.
Insulin-like growth factor-I and breast cancer therapy.
Clin Cancer Res
; 11(2 Pt 2): 944s-50s, 2005 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15701891
8.
Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer.
PLoS One
; 11(3): e0150564, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26991655
9.
Stratification and therapeutic potential of PML in metastatic breast cancer.
Nat Commun
; 7: 12595, 2016 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27553708
10.
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
Clin Cancer Res
; 21(24): 5499-5510, 2015 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26272063
11.
Insulin-like growth factor-I and cancer risk.
Growth Horm IGF Res
; 14(4): 261-9, 2004 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15231294
12.
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.
J Clin Invest
; 123(6): 2551-63, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23635776
13.
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
Sci Transl Med
; 5(196): 196ra99, 2013 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-23903756
14.
Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
Clin Cancer Res
; 18(9): 2603-12, 2012 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22407832
15.
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.
Cancer Discov
; 2(11): 1048-63, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22915751
16.
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
Cancer Discov
; 2(11): 1036-47, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22915752
17.
The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells.
Mol Endocrinol
; 25(3): 516-28, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21292829